1. Home
  2. PDT vs BWAY Comparison

PDT vs BWAY Comparison

Compare PDT & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo John Hancock Premium Dividend Fund

PDT

John Hancock Premium Dividend Fund

HOLD

Current Price

$12.76

Market Cap

653.2M

Sector

Finance

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$14.47

Market Cap

578.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDT
BWAY
Founded
N/A
2003
Country
United States
Israel
Employees
N/A
129
Industry
Finance Companies
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
653.2M
578.5M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
PDT
BWAY
Price
$12.76
$14.47
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.25
AVG Volume (30 Days)
134.9K
102.7K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$309.69
Revenue Next Year
N/A
$26.21
P/E Ratio
N/A
$81.98
Revenue Growth
N/A
N/A
52 Week Low
$12.53
$11.35
52 Week High
$13.65
$26.63

Technical Indicators

Market Signals
Indicator
PDT
BWAY
Relative Strength Index (RSI) 45.63 48.14
Support Level $12.60 $14.53
Resistance Level $12.92 $16.51
Average True Range (ATR) 0.13 0.62
MACD -0.01 0.05
Stochastic Oscillator 46.15 69.29

Price Performance

Historical Comparison
PDT
BWAY

About PDT John Hancock Premium Dividend Fund

John Hancock Premium Div Fund is a United States-based closed-end management investment company. It seeks to provide a high current income consistent with modest capital growth. The fund will pursue its objective by investing in a diversified portfolio comprised of dividend-paying preferred securities and common equity securities. The portfolio composition of the fund consists of preferred securities, common stocks, corporate bonds, capital preferred securities, and short-term investments.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: